company background image
ANAB

AnaptysBio NasdaqGS:ANAB Stock Report

Last Price

US$23.15

Market Cap

US$652.5m

7D

14.5%

1Y

-0.4%

Updated

09 Aug, 2022

Data

Company Financials +
ANAB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ANAB Stock Overview

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications.

AnaptysBio, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AnaptysBio
Historical stock prices
Current Share PriceUS$23.15
52 Week HighUS$37.89
52 Week LowUS$18.20
Beta0.15
1 Month Change13.93%
3 Month Change8.48%
1 Year Change-0.43%
3 Year Change-52.75%
5 Year Change11.94%
Change since IPO36.18%

Recent News & Updates

Aug 08

AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M

AnaptysBio press release (NASDAQ:ANAB): Q2 GAAP EPS of -$1.15 misses by $0.14. Revenue of $1.21M (-96.0% Y/Y) misses by $4.4M.

Shareholder Returns

ANABUS BiotechsUS Market
7D14.5%6.3%0.3%
1Y-0.4%-25.9%-13.5%

Return vs Industry: ANAB exceeded the US Biotechs industry which returned -25.9% over the past year.

Return vs Market: ANAB exceeded the US Market which returned -13% over the past year.

Price Volatility

Is ANAB's price volatile compared to industry and market?
ANAB volatility
ANAB Average Weekly Movement9.9%
Biotechs Industry Average Movement12.8%
Market Average Movement7.9%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market3.2%

Stable Share Price: ANAB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ANAB's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005102Dan Fagahttps://www.anaptysbio.com

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.

AnaptysBio, Inc. Fundamentals Summary

How do AnaptysBio's earnings and revenue compare to its market cap?
ANAB fundamental statistics
Market CapUS$652.51m
Earnings (TTM)-US$108.01m
Revenue (TTM)US$24.09m

27.1x

P/S Ratio

-6.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ANAB income statement (TTM)
RevenueUS$24.09m
Cost of RevenueUS$98.50m
Gross Profit-US$74.41m
Other ExpensesUS$33.60m
Earnings-US$108.01m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.83
Gross Margin-308.92%
Net Profit Margin-448.43%
Debt/Equity Ratio0%

How did ANAB perform over the long term?

See historical performance and comparison